Acadia Pharmaceuticals received final market authorization in the EU for its drug DAYBU after receiving a positive opinion from the European Medicines Agency.
3 reports, 2 independent
Updated Jun 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acadia Pharmaceuticals received final market authorization in the EU for its drug DAYBU after receiving a positive opinion from the European Medicines Agency.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
-
European Commission
executive branch of the European Union
Related events
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
- AbbVie submitted an application for risankizumab approval to the European Medicines Agency.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- INmune Bio Inc. submitted an Orphan Drug Designation and Scientific Advice package to the European Medicines Agency.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.